Novel advancements in the management of hepatocellular carcinoma in 2008.
about
Sustained JNK1 activation is associated with altered histone H3 methylations in human liver cancerCombination of three-dimensional conformal radiotherapy and transcatheter arterial chemoembolisation versus transcatheter arterial chemoembolisation for primary hepatocellular carcinomaCurrent status of laparoscopic liver resection for hepatocellular carcinomaDevelopment and novel therapeutics in hepatocellular carcinoma: a reviewBrazilian society of hepatology recommendations for the diagnosis and treatment of hepatocellular carcinomaAblation techniques for primary and metastatic liver tumorsImaging Modalities for Assessment of Treatment Response to Nonsurgical Hepatocellular Carcinoma Therapy: Contrast-Enhanced US, CT, and MRITransarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging systemNanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinomaAdvanced hepatocellular carcinoma and sorafenib: Diagnosis, indications, clinical and radiological follow-upManagement of "very early" hepatocellular carcinoma on cirrhotic patientsSystemic therapy of hepatocellular carcinoma: current status and future perspectivesTherapeutic response assessment of RFA for HCC: contrast-enhanced US, CT and MRI.Surveillance for hepatocellular carcinoma.Comparative Efficacy of Interventional Therapies for Early-stage Hepatocellular Carcinoma: A PRISMA-compliant Systematic Review and Network Meta-analysisCancer and liver cirrhosis: implications on prognosis and managementEag1 channels as potential early-stage biomarkers of hepatocellular carcinomaPrevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challengesMolecular classification and novel targets in hepatocellular carcinoma: recent advancements2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinomaComparable Outcomes of Ultrasound versus Computed Tomography in the Guidance of Radiofrequency Ablation for Hepatocellular Carcinoma.Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinomaAsian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Contrast enhanced ultrasound: Roles in immediate post-procedural and 24-h evaluation of the effectiveness of thermal ablation of liver tumorsPathway and network approaches for identification of cancer signature markers from omics data.Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC.Outcomes of patients with benign liver diseases undergoing living donor versus deceased donor liver transplantationEarly and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study.Percutaneous ablation for small hepatocellular carcinoma.Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma.Present and future possibilities for early diagnosis of hepatocellular carcinomaAlpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma.Irreversible electroporation therapy in the liver: longitudinal efficacy studies in a rat model of hepatocellular carcinoma.Value of radiofrequency ablation in the treatment of hepatocellular carcinomaApplication of tumor-node-metastasis staging 2002 version in locally advanced hepatocellular carcinoma: is it predictive of surgical outcome?Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validationMiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathwaysTAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells
P2860
Q24170091-2DCEEE7E-F228-4D64-A2A1-708A0CBF1816Q26471711-90384CDF-18D9-4792-B054-E34828AA89A9Q26745875-17FB5B61-1716-4AFE-AEF4-810FA4152287Q26752854-9A3E0EE5-364C-41D4-8DC0-3C627B767003Q26766707-2A00F5C8-0AD6-4474-8C14-A0CB20F0952BQ26770019-74666D5D-1609-4EE3-B3C0-A950D38E961EQ26772233-2BD57D7F-8485-4465-8B99-F86840F24B9FQ26784223-867ACE47-A450-4301-AE48-A5BBF3F21F03Q26823523-6DC45FB9-D226-423E-9A1B-DB2C367CC5BDQ26851033-E13B94B9-53F7-45A1-B0E2-14F29A8EE8CCQ26864406-A88C6F11-E076-46F0-821C-5B765F999A64Q26865844-2CFCF81E-4355-4FE1-B454-ED19CD23ACA4Q27016138-0E7000CE-E229-4E71-8533-A0ACE8B5D2D9Q27690269-E8E707CC-7408-4EB7-AE3E-BDA801B62208Q28067018-42752783-4BB5-4F75-9C16-AE4C24A6EE27Q28068579-BC1744D6-33BF-4BEF-AFE6-40133BA3A9E4Q28069313-AAB157E7-AE1B-40C6-86C4-0F0312CD098EQ28272678-45641210-CE3C-4E18-B176-FD7CF7BAD462Q28383646-1F8C5F9F-2FB7-4B50-93B0-38345705E2E8Q28392783-D88DE8C3-EF02-4C35-9E0A-D9D47865797BQ28394414-ACEEB37E-46EF-4B30-94D2-47FA7A16DA7AQ28469495-C4375F10-7ADA-4EA7-A107-FC8260D78288Q30453939-0582FAEA-9667-47B4-9318-279A5FB184DFQ30458109-7B300393-68D2-40AF-A1C6-6C954269B067Q30479629-F7920F5D-308E-4A09-93EA-6E67E9C68404Q30533586-CF31E123-0C08-498A-B110-C2795D42ECCBQ30882475-921AF7AF-1EFB-46AE-9D95-108BF776FB3AQ30988387-2B7D694E-EF27-4836-AD62-E48109EE4F3CQ31040993-B2D28208-EA4F-4A74-ACD5-FF3D3B5C754DQ33403106-8749B337-FC27-472F-A2D4-8E83971CF743Q33427579-D12AD719-3A7A-4D24-8DC3-498D797E6801Q33443502-57F17133-58F7-42D0-BC83-5F6C156D161AQ33612167-B5ECD1E9-5D11-4649-9113-3AFDE772DCCBQ33622809-B86196BE-3F63-432A-A29F-880B5F97AE55Q33658239-966865E2-0D3F-4832-ADCA-32F373DB55AFQ33661046-9FD70E56-478D-49F0-8DB4-13F8E4168182Q33711636-43DF40DD-A0D9-4C77-A0F6-AC30940D8A53Q33751830-F6D2DF0F-69B1-4AF6-8435-486A6AFF6A6BQ33761894-464BDF35-1C7E-47AC-A6B9-ADE17C8DAFB7Q33769475-8ABC8AD1-A756-468C-AC56-87EBFF680C85
P2860
Novel advancements in the management of hepatocellular carcinoma in 2008.
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Novel advancements in the management of hepatocellular carcinoma in 2008.
@ast
Novel advancements in the management of hepatocellular carcinoma in 2008.
@en
Novel advancements in the management of hepatocellular carcinoma in 2008.
@nl
type
label
Novel advancements in the management of hepatocellular carcinoma in 2008.
@ast
Novel advancements in the management of hepatocellular carcinoma in 2008.
@en
Novel advancements in the management of hepatocellular carcinoma in 2008.
@nl
prefLabel
Novel advancements in the management of hepatocellular carcinoma in 2008.
@ast
Novel advancements in the management of hepatocellular carcinoma in 2008.
@en
Novel advancements in the management of hepatocellular carcinoma in 2008.
@nl
P1476
Novel advancements in the management of hepatocellular carcinoma in 2008.
@en
P2093
Jordi Bruix
P304
P356
10.1016/J.JHEP.2008.01.022
P478
48 Suppl 1
P577
2008-02-12T00:00:00Z